Century Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Century Therapeutics Current Ratio Growth & History (IPSC)
Century Therapeutics's current ratio was 5.97 for fiscal 2025.
View full Century Therapeutics company overviewCentury Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 5.97 | 4.48 | +299.34% |
| 2024 | 2024-12-31 | 1.50 | −8.42 | −84.92% |
| 2023 | 2023-12-31 | 9.92 | −0.80 | −7.51% |
| 2022 | 2022-12-31 | 10.72 | −3.85 | −26.42% |
| 2021 | 2021-12-31 | 14.57 | 8.07 | +124.02% |
| 2020 | 2020-12-31 | 6.51 | — | — |
Century Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 8.28 | −2.43 | −22.72% |
| Q1 2026 | 2026-03-31 | 10.25 | −1.45 | −12.37% |
| Q4 2025 | 2025-12-31 | 5.97 | 4.48 | +299.34% |
| Q3 2025 | 2025-09-30 | 6.25 | −4.14 | −39.85% |
| Q2 2025 | 2025-06-30 | 10.72 | 0.10 | +0.91% |
| Q1 2025 | 2025-03-31 | 11.70 | −0.74 | −5.96% |
| Q4 2024 | 2024-12-31 | 1.50 | −8.42 | −84.92% |
| Q3 2024 | 2024-09-30 | 10.39 | 1.89 | +22.28% |
| Q2 2024 | 2024-06-30 | 10.62 | 2.20 | +26.15% |
| Q1 2024 | 2024-03-31 | 12.44 | 3.19 | +34.54% |
| Q4 2023 | 2023-12-31 | 9.92 | −0.80 | −7.51% |
| Q3 2023 | 2023-09-30 | 8.50 | −4.94 | −36.76% |
| Q2 2023 | 2023-06-30 | 8.42 | −9.38 | −52.70% |
| Q1 2023 | 2023-03-31 | 9.24 | −7.38 | −44.38% |
| Q4 2022 | 2022-12-31 | 10.72 | −3.85 | −26.42% |
| Q3 2022 | 2022-09-30 | 13.44 | −1.68 | −11.11% |
| Q2 2022 | 2022-06-30 | 17.79 | −1.17 | −6.19% |
| Q1 2022 | 2022-03-31 | 16.62 | — | — |
| Q4 2021 | 2021-12-31 | 14.57 | 8.07 | +124.02% |
| Q3 2021 | 2021-09-30 | 15.12 | — | — |
| Q2 2021 | 2021-06-30 | 18.97 | — | — |
| Q4 2020 | 2020-12-31 | 6.51 | — | — |
Century Therapeutics current ratio trends
Over the last five fiscal years, Century Therapeutics's current ratio decreased from 6.51 to 5.97, a change of −0.53. The latest reported quarter, Q2 2026, shows 8.28.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Century Therapeutics source filings ↗